This model showed higher accuracy than conventional biomarkers in detecting patients with resectable pancreatic cancer; the sensitivity of this method for discrimination of patients with resectable pancreatic cancer was 77.8%, which was higher than that of CA19–9 or CEA even in their validation study. The gene discussed is CEACAM5; the disease is pancreatic neoplasm.